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Abstract
Background: The current study aims to evaluate and compare the efficacy of post-operative chemotherapy using
paclitaxel plus carboplatin or nedaplatin in patients with ovarian cancer, as well as the effects of different combinational
therapies on the survival times of patients.
Methods: Ninety-four patients were recruited for the study. These ovarian cancer patients were admitted into the
Cancer Hospital Affiliated with Harbin Medical University for surgery from January 2008 to October 2009. They were
divided into different groups according to their post-operative chemotherapy schemes: paclitaxel plus carboplatin (CBP
group, n = 48) and paclitaxel plus nedaplatin (NDP group, n = 46). Variance analysis was used to compare the effects of
different chemotherapy schemes and pathological types of ovarian cancer on the level of CA125 in serum at different
treatment time points. Univariate and multivariate analyses were employed to evaluate the survival times of patients in
different groups and pathological types and ages.
Results: No significant differences were observed regarding the effects of various chemotherapy schemes (P = 0.561)
and pathological types (P = 0.903) on the level of CA125 in serum of patients with ovarian cancer. However, the
duration of chemotherapy had a profound impact on the level of CA125 in serum (P < 0.001). The survival times
of patients was not affected by age (P = 0.101) and pathological type of ovarian cancer (P = 0.94) significantly.
However, it was significantly affected by the chemotherapy scheme.
Conclusions: Combined chemotherapy using carboplatin plus paclitaxel should be considered as the preferred
treatment scheme for the initial treatment of ovarian cancer.
Keywords: Ovarian cancer, Carboplatin, Nedaplatin, Survival time, CA125
Background
Ovarian cancer is the fifth most common cause of cancer
death in women and is the most common cause of death
by a gynecological tumor, which seriously threatens the
health of women [1, 2]. Due to the insidious onset, rapid
progression, easy intraperitoneal dissemination and me-
tastasis in the early stage, and lack of effective early diag-
nosis of ovarian cancer, approximately 70 % patients are
diagnosed in the advanced stages of the disease. So, cytor-
eductive surgery followed by adjuvant chemotherapy in
the form of combined taxane and platinum remains the
primary treatment [3, 4]. Chemotherapy using paclitaxel
combined with platinum has been used to treat patients
with ovarian cancer since the late twentieth century [4].
Due to less toxicity, easier administration, and higher
patient tolerance of carboplatin compared with cisplatin, a
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chemotherapy regimen consisting of carboplatin plus pac-
litaxel has gradually replaced cisplatin plus paclitaxel,
becoming the preferred treatment scheme in clinical prac-
tice for advanced ovarian cancer [5]. And, the overall 5-
year survival rate of patients with ovarian cancer is ap-
proximately 20–30 % [6]. However, the resistance of car-
boplatin is still unresolved and this would lead to the
recurrence of cancer indirectly.
Nedaplatin is a second-generation platinum-based
chemotherapy drug with a similar mechanism of action
to that of cisplatin, which can crosslink with DNA in a
non-cell-cycle-specific manner. Its dissolution rate in
plasma is ten times faster than that of cisplatin. More-
over, nedaplatin can be used without hydration. Further-
more, there is no cross resistance between nedaplatin
and cisplatin or carboplatin [7]. Clinical studies showed
that the effectiveness of nedaplatin plus paclitaxel is
higher than that of carboplatin plus paclitaxel in the
treatment of a malignant tumor. So, there is a tendency
that nedaplatin would substitute carboplatin in clinic be-
cause the toxicity of nedaplatin is lower than that of car-
boplatin [8, 9]. Presently, both nedaplatin plus paclitaxel
and carboplatin plus paclitaxel are feasible in the treat-
ment of some malignant tumors [10]. However, there
are few applications and limited evaluations of the effi-
cacy of the clinical usage of nedaplatin plus paclitaxel in
ovarian cancer, and the clinical efficacy and safety of
paclitaxel plus nedaplatin in ovarian cancer still needs
further validation.
Carbohydrate antigen 125 (CA125) is a kind of glyco-
protein and a classical marker for early diagnosis and re-
currence of ovarian cancer [11, 12]. The level of CA125
in serum is positively correlated with the degree of
tumor malignancy and the possibility of recurrence. At
the same time, in the same patient with ovarian cancer,
rising and falling of CA125 value reflect the expanding
and reduction of the lesions to a certain extent [13, 14].
In the current study, firstly, influences of different
ovarian cancer pathologies, chemotherapy schemes, and
treatment durations on the level of CA125 in serum
were analyzed. Secondly, effects of paclitaxel plus carbo-
platin or nedaplatin on the survival times of patients
with ovarian cancer were evaluated and compared. The
results of this study would provide certain guidance for
the clinical selection of chemotherapy schemes.
Methods
Inclusion criteria
From January 2008 to October 2009, patients with ovarian
cancer admitted into the Gynaecology Department of the
Cancer Hospital Affiliated to Harbin Medical University,
Heilongjiang Province of China, who underwent ovarian
cancer cytoreductive surgery and six courses of chemo-
therapy, and met the following criteria were recruited.
1. Patients with complete medical records and follow-
up data from January 2013 to October 2014.
2. Patients diagnosed with primary and poorly
differentiated epithelial ovarian adenocarcinoma in
the post-operative pathological histological
examination.
3. Phase IIIc patients who had received first surgery
(cytoreductive surgery) in our hospital, with less
than four lymph nodes metastasis, the maximum
diameter of the residual tumor is smaller than 1 cm.
4. No history of chemotherapy before surgery.
5. The level of CA125 in serum had been measured
before surgery and chemotherapy, and the level of
CA125 in serum before surgery must be higher than
the normal level (35 U/ml).
6. Patients received combination chemotherapy of
paclitaxel plus carboplatin or nedaplatin after
surgery.
Grouping and the regimen of chemotherapy
Patients who met the inclusion criteria were divided into
different groups based on their post-operative chemo-
therapy schemes: carboplatin plus paclitaxel (CBP group,
48 cases) and nedaplatin plus paclitaxel (NDP group, 46
cases). All patients in the two groups received combined
chemotherapy. The detailed regimen in CBP group was
paclitaxel (135–175 mg/m2) and carboplatin (area under
the curve, five), administered intravenously and/or intra-
peritoneally every 3 weeks for six cycles. Similarly, the
detailed regimen in NDP group was paclitaxel (135–
175 mg/m2) and nedaplatin (80–100 mg/m2), adminis-
tered intravenously and/or intraperitoneally every 3 weeks
for six cycles.
Determination of the level of CA125 in serum
For each patient, 3 ml of fasting venous blood was col-
lected in a sterile vacuum blood tube via the conventional
method. The collected blood samples were kept at room
temperature for 0.5 h and then centrifuged at 3000 rpm/
min for 10 min to obtain the serum samples, which were
stored at −80 °C until analysis. The current study employed
the electrochemical luminescence method to measure the
level of CA125 in serum by using a chemiluminescence
immunoassay analyzer and accompanied reagents pur-
chased from Roche, Switzerland. All measurements were
conducted strictly according to the standard operating pro-
cedures of the instruments and manufacturer’s instruc-
tions. The level of CA125 in serum was considered to be
positive when it is higher than 35 U/ml.
Statistical analysis
EpiData 3.02 software was used for data entry, and all stat-
istical analyses were performed using SPSS 17.0. Some re-
sults are presented as means ± standard deviation (SD).
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Student’s t test and the chi-square test were used to com-
pare the ages and the pathological type of ovarian cancer
between the two groups. Repeated analysis of variance
was employed to compare the effects of different chemo-
therapy schemes and the pathological type of ovarian can-
cer on the level of CA125 in serum at different time
points. Furthermore, Kaplan–Meier (KM) univariate sur-
vival analysis was used to compare the effects of different
chemotherapy schemes and the pathological types of ovar-
ian cancer on the survival times of patients. In addition,
Cox regression analysis was employed to assess the
influences of various factors on the survival times of pa-
tients with ovarian cancer. All tests were two-tailed, and a
P value <0.05 was considered to be statistically significant.
Results
Comparisons of age and pathological types of patients
between the two groups
Among the 94 patients, the youngest was 26 years of age
and the oldest was 80 years of age. No statistically sig-
nificant differences in average age and pathological types
were seen (P age = 0.558, P pathological types = 0.763), indi-
cating that they were balanced and comparable between
the two groups. Specific data are listed in Table 1.
The effects of different chemotherapy schemes, durations,
and pathological types on the level of CA125 in serum
There was no significant difference between the level of
CA125 in serum of patients in the different groups and
between different pathological types (Fchemotherapy scheme
= 0.342, P = 0.561; F pathological types = 0.015, P = 0.903).
The level of CA125 in serum of the different groups and
pathological types are shown in Fig. 1. However, with
the duration of chemotherapy increased, the level of
CA125 in serum significantly decreased (F = 41.395,
P < 0.001).
The results of KM univariate survival analysis
The results demonstrated that there was a significant
difference in survival times between patients of different
chemotherapy schemes ( χ 2 = 4.801, P = 0.028). Namely,
the survival time of patients in the CBP group was sig-
nificantly longer than that in the NDP group (Fig. 2).
However, there was no significant difference in survival
times of patients with different pathological types (χ 2 =
0.447, P = 0.504, Fig. 3).
The results of Cox multivariate survival analysis
The results of Cox regression analysis showed that the
age and pathological types of patients did not affect their
Fig. 1 The level of CA125 in serum of different groups and pathological types. a The level of CA125 in serum of patients in different groups.
b The level of CA125 in serum of patients with different pathological types
Table 1 Comparisons of ages and pathological types of patients between two groups
CBP (n = 48) NDP (n = 46) Statistics P value
Age 50.75 ± 8.566 51.87 ± 9.854 t = 0.589 0.558
Pathological type χ2 = 0.091 0.763
Poorly differentiated adenocarcinoma (30) 16 14
Papillary serous adenocarcinoma (64) 32 32
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survival times (P age = 0.101, P pathological types = 0.94),
while different chemotherapy schemes significantly af-
fected the survival times of patients (P = 0.029). The re-
sults also indicated that those patients in the CBP group
had a lower risk to die, with a value of 0.501 (95 % CI:
0.269–0.932) when compared to those in the NDP
group, signifying that the survival time of patients in the
CBP group was longer than those in the NDP group.
The data is presented in Table 2.
Discussion
CA125, found in 1981, is an inhomogeneous, highly mo-
lecular mucin-like glucoprotein. In patients with effect-
ive surgical treatment and chemotherapy, the level of
CA125 in serum decreases quickly. In cases of recur-
rence and drug resistance, the level of CA125 in serum
elevates prior to the clinical symptoms, indicating that
CA125 is an early marker for recurrence and drug resist-
ance. In the current study, post-operative chemotherapy
lowered the level of CA125 in serum of patients in both
the groups; especially with a longer duration of post-
operative chemotherapy, the level of CA125 in serum
significantly decreased. The results suggested that the
duration of chemotherapy is the main factor affecting
the level of CA125 in serum of patients. This result is
consistent with previous studies. Li et al. found that the
recurrence rate of ovarian cancer closely correlated with
the type of post-operative chemotherapy; at the same
time, completion of post-operative chemotherapy was a
significant factor influencing the prognosis. And, they
found that the recurrence rate of patients who com-
pleted post-operative chemotherapy (27.6 %) was signifi-
cantly lower than that of the patients who did not
(47.3 %) [15].
Fig. 2 The influence of different chemotherapy schemes on the survival time of patients
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Carboplatin in combination with paclitaxel has been
broadly accepted as first-line chemotherapy for advanced
epithelial ovarian cancer for many years [16, 17]. During
the initial design of this study, researchers hypothesized
that the survival time of patients in the NDP group would
be longer than those in the CBP group because less side
effects and higher patient tolerance of nedaplatin. And,
some literatures partly support this hypothesis [18, 19].
Unexpectedly, although there was no significant difference
in the level of CA125 in serum between patients receiving
different chemotherapy schemes, the survival time of pa-
tients in the CBP group was longer than those in the NDP
group. In addition, the price of nedaplatin is about 2.5 times
that of carboplatin and this would increase the economic
burden of patients preferring less toxicity. So, according to
the results of this study, carboplatin plus paclitaxel should
be continued in the treatment of ovarian cancer.
Pathological type of ovarian cancer affects the degree of
malignancy and, subsequently, different rates of recurrence.
Previous multivariate analysis showed that the pathological
type was an independent risk factor for the recurrence of
ovarian cancer. Serous carcinoma usually recurred, while
mucinous carcinoma had better prognosis [20]. Another
research reported that, relative to serous papillary cystade-
nocarcinoma and poorly differentiated carcinoma, papillary
mucinous cystadenocarcinoma has better prognosis [21].
Fig. 3 The influence of different pathological types on the survival time of patients
Table 2 The results of Cox multivariate survival analysis




Age 2.694 0.101 1.03 0.994 1.068
Chemotherapy schemes 4.756 0.029 0.501 0.269 0.932
Pathological type 0.006 0.94 1.025 0.535 1.963
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Our study also proved this view indirectly. In this study, we
only focused on two pathological types of ovarian cancer
with poor prognosis, including poorly differentiated carcin-
oma and serous papillary cystadenocarcinoma. And, there
were no significant differences in the level of CA125 in
serum and the survival time among patients with different
pathological types at different time points.
Conclusions
So, in this study, a chemotherapy scheme was the main
factor to affect the survival time of patients with ovarian
cancer. And, combined chemotherapy using carboplatin
plus paclitaxel should be considered as the preferred treat-
ment scheme for the initial treatment of ovarian cancer.
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